A Novel Classification of Non–B-, Non–T-ALL Based on the Expression of SL Chain, μH Chain, and Pre-BCR, and the Incidence of Each Group Observed in This Study
| Cytoplasmic Expression . | No. of Bone Marrow Samples [A] . | No. of Peripheral Blood Samples [B] . | [A] + [B] (%) . | Classification Proposed in This Study . | |||
|---|---|---|---|---|---|---|---|
| SL Chain (λ5 and/or VpreB) . | μH Chain . | Pre-BCR . | L Chain . | ||||
| − | − | − | − | 3 | 0 | 3 (5) | Pro–B-I |
| +3-150 | − | − | − | 17 | 17 | 34 (61) | Pro–B-II |
| +3-151 | + | − | − | 4 | 2 | 6 (11) | Pre-B (pre-BCR−) |
| +3-152 | + | + | − | 7 | 6 | 13 (23) | Pre-B (pre-BCR+) |
| Total | 31 | 25 | 56 (100) | ||||
| Cytoplasmic Expression . | No. of Bone Marrow Samples [A] . | No. of Peripheral Blood Samples [B] . | [A] + [B] (%) . | Classification Proposed in This Study . | |||
|---|---|---|---|---|---|---|---|
| SL Chain (λ5 and/or VpreB) . | μH Chain . | Pre-BCR . | L Chain . | ||||
| − | − | − | − | 3 | 0 | 3 (5) | Pro–B-I |
| +3-150 | − | − | − | 17 | 17 | 34 (61) | Pro–B-II |
| +3-151 | + | − | − | 4 | 2 | 6 (11) | Pre-B (pre-BCR−) |
| +3-152 | + | + | − | 7 | 6 | 13 (23) | Pre-B (pre-BCR+) |
| Total | 31 | 25 | 56 (100) | ||||
Among 34 samples in this group, 24 cases were positive for both λ5 and VpreB, 3 were positive for λ5 only, and 7 cases were positive for VpreB only.
Among 6 samples in this group, 5 cases were positive for both λ5 and VpreB, and one case was positive for λ5 only.
All 13 samples in this group were positive for both λ5 and VpreB.